Evidence map›Paper›PMID 39729257›Full record

ArticleDocumenta ophthalmologica. Advances in ophthalmology2025

Anti-VEGF therapy for proliferative diabetic retinopathy in Kearns-Sayre syndrome.

Vannessa Leung, James G Wong, John R Grigg

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Documenta ophthalmologica. Advances in ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Aflibercept for the treatment of pigmentary retinopathy in Kearns-Sayre syndrome?Documenta ophthalmologica. Advances in ophthalmology · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Vannessa LeungSave Sight Institute Faculty of Medicine and Health, University of Sydney, Sydney, Australia. vleu4579@uni.sydney.edu.au.ORCID 0000-0001-8431-9040
James G WongSave Sight Institute Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
John R GriggSave Sight Institute Faculty of Medicine and Health, University of Sydney, Sydney, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeMultiple mitochondrial syndromes, such as Kearns-Sayre, involve the concurrence of diabetes mellitus and inherited pigmentary retinopathy. It is rare, however, for proliferative disease to develop in these patients as existing inner retinal dysfunction is thought to be protective.

methodsTo our knowledge this is the first description of proliferative diabetic retinopathy (PDR) in Kearns-Sayre syndrome.

conclusionA number of additional considerations need to be recognised when treating PDR in Kearns-Sayre syndrome. Given the risk of further visual field losses with panretinal photocoagulation, there should be a preference for primary anti-VEGF therapy in a compliant patient. PDR in inherited retinal disease appears to be very anti-VEGF responsive and may not require the standard monthly frequency of treatment, even from initiation.

Indexed as

Angiogenesis InhibitorsDiabetic RetinopathyKearns-Sayre SyndromeVascular Endothelial Growth Factor ABevacizumabHumansIntravitreal InjectionsRanibizumabAngiogenesis InhibitorsBevacizumabRanibizumabVascular Endothelial Growth Factor AVEGFA protein, humanAfliberceptAnti-VEGFKearns-SayreProliferative diabetic retinopathy

Identifiers

PMID39729257

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.